"There is no real reason, given the great progress and runs on the board that the SP should be where it is"
I have to disagree with you. Although BTM is doing well, PNV have not delivered on other fronts.
A case study: Hernia repair. So close but ....
24 February 2014
12 August 2014
23 February 2015
29 October 2015
Change of tack... 19 February 2016
2016-2021
In house development completed, New tech developed can be leveraged, equipment ordered, new plant commissioning delayed (covid).
October 2021
05 Nov 2021 MD resigns
14 December 2021 Bingo!
23 August 2023
Nearly ten years to go from a successful feasibility study, with a partner of choice (who, I believe, succeeded with the help of another ASX listed company), to a focused approach after failing a pre-clinical study. Any investor's dream....
I could spend more time and list market releases for:
Synpath: From a successful feasibility study in 2021 (supposed to iron out any issues) to a 9 months (and counting) protocol review after 25 patients in 2022.
Breast sling: 2017 Establishment Lab partnership, Dec 2020 development brought back in house, 2023 ?????
etc.....
Getting disillusioned, page-70
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.31 |
Change
-0.025(1.07%) |
Mkt cap ! $1.597B | |||
| Open | High | Low | Value | Volume |
| $2.38 | $2.38 | $2.30 | $1.723M | 741.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 24110 | $2.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.31 | 34267 | 29 |
View Market Depth
| Last trade - 15.08pm 11/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |